The Platelet/Monocyte Ratio Before Treatment Predicts Prognosis in Solid Childhood Cancers

Authors

  • Özlem Terzi Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Cengiz Bayram Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey
  • Ali Ayçiçek Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Ezgi Uysalol Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Cennet Nur Baş Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Hüseyin Avni Solgun Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Tuba Tahtakesen Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Esra Arslantaş Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.
  • Sibel Tekgündüz Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.

DOI:

https://doi.org/10.31964/mltj.v8i1.482

Abstract

The prognostic value of thrombocytosis and inflammatory biomarkers in adult cancer patients has been the subject of many studies. This study investigated the role of platelet count and other inflammatory biomarkers in the prognosis of solid childhood tumours. The data of 176 pediatric patients diagnosed with solid tumours were evaluated retrospectively; 150 patients still under follow-up were included in the study. We examined the relationship between platelet count, platelet/neutrophil ratio (PNR), platelet/lymphocyte ratio (PLR) and platelet/monocyte ratio (PMR) at the time of diagnosis on survival. The mean age of diagnosis was 7.91 ± 5.75 years, and 60.7% were male. The mean platelet count of the patients was 424.326 ± 167197.32. The median (range) follow-up was 13 (1-68) months. Relapse was seen in 18% of the patients, and 9.3% died. The relationship between PMR and overall survival (OS) and event-free survival times (EFS) was statistically significant (p=0.002 and p=0.016, respectively). However, no statistically significant association was found for PLR or PNR. Overall survival and EFS were significantly poorer in this cohort in patients with high pretreatment PMR.

References

Buergy D, Wenz F, Groden C, Brockmann M. Tumor platelet interaction in solid tumours. Int J Cancer, 2012 Jun 15;130(12):2747-60.

Condeelis J , Pollard J. Macrophages obligate partners for tumour cell migration, invasion, and metastasis. Cell, 2006 Jan 27;124(2):263-6.

Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol, 2015 Oct;12(10):584-96.

Cui M, Li N , Liu X , Yun Z, Niu Y , Zhang Y, Gao B, Liu T, Wang R . Platelet distribution width correlates with prognosis of non-small cell lung cancer. Sci Rep, 2017 Jun 14;7(1):3456.

Desai S, Prickril B, Rasooly A. Mechanisms of phytonutrient modulation of Cyclooxygenase-2 (COX-2) and cancer-related inflammation. Nutr Cancer, 2018 Apr;70(3):350-375.

Giannakeas V, Narod S. Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. JAMA Netw Open. 2021 Aug 2;4(8):e2120633.

Giannakeas V, Kotsopoulos J, Brooks J, Cheung M, Rosella A, Lipscombe L, Akbari M, Austin P, Narod S. Platelet Count and Survival after Cancer. Cancers (Basel), 2022 Jan 21;14(3):549.

Goubran H, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost, 2014 Apr;40(3):296-305.

Huang X, Chen W, Zhang X, Wu C, Zhang C, Shuang-Shuang Sun, Jian Wu. An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis. Disease markers, 2017;2017:1053125.

Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol, 2002 Apr;9(3):287-91.

Kundu J, Surh Y. Inflammation: gearing the journey to cancer. Mutat Res, 2008 Jul-Aug;659(1-2):15-30.

Lee E, Cameron S. Cancer and thrombotic risk: The platelet paradigm. Front Cardiovasc Med, 2017 Nov 7;4:67.

Li D, Hao X, Ma T, Dai H, Song Y. The Prognostic Value of Platelet-to-Lymphocyte Ratio in Urological Cancers: A Meta-Analysis. Scientific reports, 2017 Nov 13;7(1):15387.

Lu C, Chang K, Chou F, Cheng C, Liu C. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol, 2007 Mar;43(3):283-8.

Ma W, Zhang P, Qi J, Gu L, Zang M, Yao H, Shi X, Wang C, Jiang Y. Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. Scientific reports, 2016 Oct 14;6:35378.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature, 2008 Jul 24;454(7203):436-44.

Matowicka-Karna J. Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases. Postepy Hig Med Dosw (Online), 2016 Apr 13;70:305-12.

Peterson J, Zurakowski D, Italiano J, Michel L, Connors S, Oenick M, D'Amato J, Klement G, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis, 2012 Jun;15(2):265-73.

Qingjian Y, Zhixi W, Tingting X, Dong L, Yuebo Y, Hong T. Pretreatment thrombocytosis predicts prognosis of endometrial cancer: A meta analysis of 11 studies. Exp Ther Med, 2020 Jan;19(1):359-366.

Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970 Jan;25(1):135-40.

Riess L. Zur pathologischen anatomie des blutes. Arch Anat Physiol Wiss Med, 1872;39: 237 249.

Seizer P, May AE. Platelets and matrix metalloproteinases. Thromb Haemost, 2013 Nov;110(5):903-9.

Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg, 2004 May;198(5):737-41.

Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics. Cancer J Clin, 2022 Jan;72(1):7-33.

Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol, 2012;30:1-22.

Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, Kitajima M. Platelets counts closely correlate with the disease free survival interval of pancreatic cancer patients. Hepatogastroenterology, 2004 May-Jun;51(57):847-53.

Symbas NP, Townsend NP, Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int, 2000 Aug;86(3):203-7.

Tan D, Fu Y, Su Q, Wang H. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore), 2016 Jun;95(24):e3837.

Ulich TR, Del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin one and tumour necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol, 1987 Nov 15;139(10):3406-15.

Xia W , Chen W, Zhang Z , Wu D, Wu P, Chen Z, Li C, Huang J. Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A meta-analysis. PLoS One, 2015 Apr 9;10(4):e0123484.

Ye Q, Cheng J, Ye M, Liu D, Zhang Y. Association of pretreatment thrombocytosis with prognosis in ovarian cancer: A systematic review and meta-analysis. J Gynecol Oncol, 2019 Jan;30(1):e5.

Yodying H, Matsuda A, Miyashita M , Matsumoto S , Sakurazawa N , Yamada M, Uchida E. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis. Annals of surgical oncology, 2016 Feb;23(2):646-54.

Zhang H, Gao H, Zhang B, Zhang L, Wang C . Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Scientific reports, 2016 Mar 4;6:22618.

Zhang M, Huang X, Song Y, Gao P, Sun J, Wang Z. High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis. BioMed research international, 2017;2017:9503025.

Zhao Q, Yuan Z, Zhang H, Zhang X, Wang H, Wang Z, Duan G. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. Int J Cancer, 2016 Jul 1;139(1):164-70.

Downloads

Published

2022-12-19

How to Cite

Terzi, Özlem, Bayram, C. ., Ayçiçek, A., Uysalol, E., Nur Baş, C. ., Solgun, H. A., Tahtakesen, T. ., Arslantaş, E. ., & Tekgündüz, S. (2022). The Platelet/Monocyte Ratio Before Treatment Predicts Prognosis in Solid Childhood Cancers. Medical Laboratory Technology Journal, 8(2), 168–176. https://doi.org/10.31964/mltj.v8i1.482

Issue

Vol. 8 No. 2 (2022): December

Section

Articles

License

Copyright (c) 2022 Özlem Terzi, Cengiz Bayram, Ali Ayçiçek, Ezgi Uysalol, Cennet Nur Baş, Hüseyin Avni Solgun, Tuba Tahtakesen, Esra Arslantaş, Sibel Tekgündüz

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:


BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.